Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (Diluted Average) (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Shares Outstanding (Diluted Average) for 15 consecutive years, with $66.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 40.27% to $66.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.8 million through Dec 2025, up 40.27% year-over-year, with the annual reading at $66.8 million for FY2025, 40.27% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $66.8 million in Q4 2025 for Cardiff Oncology, roughly flat from $66.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $66.9 million in Q3 2025 to a low of $37.2 million in Q1 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $47.8 million across 5 years, with a median of $44.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 161.99% in 2021 and later increased 0.0% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $39.0 million in 2021, then rose by 11.71% to $43.6 million in 2022, then grew by 2.47% to $44.7 million in 2023, then rose by 6.65% to $47.6 million in 2024, then surged by 40.27% to $66.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CRDF at $66.8 million in Q4 2025, $66.9 million in Q3 2025, and $66.5 million in Q2 2025.